nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—ADRA1D—polycystic ovary syndrome	0.247	0.412	CbGaD
Imipramine—ADRA1B—polycystic ovary syndrome	0.211	0.352	CbGaD
Imipramine—ADRA1A—polycystic ovary syndrome	0.142	0.237	CbGaD
Imipramine—SLC22A3—Metformin—polycystic ovary syndrome	0.107	0.475	CbGbCtD
Imipramine—SLC22A2—Metformin—polycystic ovary syndrome	0.0631	0.281	CbGbCtD
Imipramine—SLC22A1—Metformin—polycystic ovary syndrome	0.0549	0.244	CbGbCtD
Imipramine—CYP2C19—urine—polycystic ovary syndrome	0.00162	0.0444	CbGeAlD
Imipramine—CYP1A2—urine—polycystic ovary syndrome	0.00132	0.0363	CbGeAlD
Imipramine—CYP2E1—urine—polycystic ovary syndrome	0.00119	0.0326	CbGeAlD
Imipramine—HTR2A—urine—polycystic ovary syndrome	0.00103	0.0284	CbGeAlD
Imipramine—KCND2—pituitary gland—polycystic ovary syndrome	0.00103	0.0282	CbGeAlD
Imipramine—KCND2—adipose tissue—polycystic ovary syndrome	0.00102	0.0281	CbGeAlD
Imipramine—CYP3A4—urine—polycystic ovary syndrome	0.000957	0.0263	CbGeAlD
Imipramine—CYP2D6—urine—polycystic ovary syndrome	0.000941	0.0258	CbGeAlD
Imipramine—KCND3—uterus—polycystic ovary syndrome	0.000912	0.025	CbGeAlD
Imipramine—KCND3—adipose tissue—polycystic ovary syndrome	0.000891	0.0245	CbGeAlD
Imipramine—KCND2—female gonad—polycystic ovary syndrome	0.000855	0.0235	CbGeAlD
Imipramine—KCND3—adrenal gland—polycystic ovary syndrome	0.0008	0.0219	CbGeAlD
Imipramine—CYP2C18—vagina—polycystic ovary syndrome	0.000675	0.0185	CbGeAlD
Imipramine—SLC22A3—embryo—polycystic ovary syndrome	0.000649	0.0178	CbGeAlD
Imipramine—CYP2C18—endocrine gland—polycystic ovary syndrome	0.000631	0.0173	CbGeAlD
Imipramine—CYP3A7—endocrine gland—polycystic ovary syndrome	0.000601	0.0165	CbGeAlD
Imipramine—ORM1—endometrium—polycystic ovary syndrome	0.000542	0.0149	CbGeAlD
Imipramine—SLC22A4—endometrium—polycystic ovary syndrome	0.000522	0.0143	CbGeAlD
Imipramine—SLC22A3—endometrium—polycystic ovary syndrome	0.000475	0.013	CbGeAlD
Imipramine—SLC22A4—pituitary gland—polycystic ovary syndrome	0.000472	0.013	CbGeAlD
Imipramine—SLC22A4—adipose tissue—polycystic ovary syndrome	0.00047	0.0129	CbGeAlD
Imipramine—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.000468	0.0322	CcSEcCtD
Imipramine—ADRA1D—endocrine gland—polycystic ovary syndrome	0.000461	0.0127	CbGeAlD
Imipramine—Breast disorder—Metformin—polycystic ovary syndrome	0.000459	0.0315	CcSEcCtD
Imipramine—SLC22A1—adipose tissue—polycystic ovary syndrome	0.000448	0.0123	CbGeAlD
Imipramine—SLC22A3—adipose tissue—polycystic ovary syndrome	0.000428	0.0117	CbGeAlD
Imipramine—SLC22A4—adrenal gland—polycystic ovary syndrome	0.000422	0.0116	CbGeAlD
Imipramine—Infestation—Metformin—polycystic ovary syndrome	0.000391	0.0268	CcSEcCtD
Imipramine—Infestation NOS—Metformin—polycystic ovary syndrome	0.000391	0.0268	CcSEcCtD
Imipramine—Drowsiness—Metformin—polycystic ovary syndrome	0.000391	0.0268	CcSEcCtD
Imipramine—SLC22A4—vagina—polycystic ovary syndrome	0.000391	0.0107	CbGeAlD
Imipramine—SLC22A3—adrenal gland—polycystic ovary syndrome	0.000384	0.0105	CbGeAlD
Imipramine—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.000383	0.0263	CcSEcCtD
Imipramine—ORM1—endocrine gland—polycystic ovary syndrome	0.00038	0.0104	CbGeAlD
Imipramine—SLC22A1—vagina—polycystic ovary syndrome	0.000372	0.0102	CbGeAlD
Imipramine—CHRM3—adipose tissue—polycystic ovary syndrome	0.000371	0.0102	CbGeAlD
Imipramine—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00037	0.0254	CcSEcCtD
Imipramine—KCNH2—endometrium—polycystic ovary syndrome	0.000365	0.01	CbGeAlD
Imipramine—SLC22A3—female gonad—polycystic ovary syndrome	0.000358	0.00982	CbGeAlD
Imipramine—SLC22A3—vagina—polycystic ovary syndrome	0.000356	0.00976	CbGeAlD
Imipramine—CHRM2—endocrine gland—polycystic ovary syndrome	0.000354	0.00973	CbGeAlD
Imipramine—Hepatitis—Metformin—polycystic ovary syndrome	0.000351	0.0241	CcSEcCtD
Imipramine—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000349	0.024	CcSEcCtD
Imipramine—SLC22A1—endocrine gland—polycystic ovary syndrome	0.000348	0.00955	CbGeAlD
Imipramine—ADRA1A—adipose tissue—polycystic ovary syndrome	0.000341	0.00935	CbGeAlD
Imipramine—KCNH2—uterus—polycystic ovary syndrome	0.000336	0.00924	CbGeAlD
Imipramine—CYP2B6—adrenal cortex—polycystic ovary syndrome	0.000336	0.00921	CbGeAlD
Imipramine—DRD2—pituitary gland—polycystic ovary syndrome	0.000335	0.0092	CbGeAlD
Imipramine—HTR2A—embryo—polycystic ovary syndrome	0.000334	0.00917	CbGeAlD
Imipramine—SLC22A3—endocrine gland—polycystic ovary syndrome	0.000333	0.00913	CbGeAlD
Imipramine—HTR1A—adrenal gland—polycystic ovary syndrome	0.000332	0.0091	CbGeAlD
Imipramine—KCNH2—pituitary gland—polycystic ovary syndrome	0.00033	0.00907	CbGeAlD
Imipramine—SLC6A2—adrenal gland—polycystic ovary syndrome	0.000329	0.00902	CbGeAlD
Imipramine—Eye disorder—Metformin—polycystic ovary syndrome	0.000328	0.0225	CcSEcCtD
Imipramine—Flushing—Metformin—polycystic ovary syndrome	0.000326	0.0224	CcSEcCtD
Imipramine—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000326	0.0224	CcSEcCtD
Imipramine—SLC6A4—endocrine gland—polycystic ovary syndrome	0.000324	0.00889	CbGeAlD
Imipramine—CHRM1—endocrine gland—polycystic ovary syndrome	0.000323	0.00885	CbGeAlD
Imipramine—Angiopathy—Metformin—polycystic ovary syndrome	0.000318	0.0219	CcSEcCtD
Imipramine—Immune system disorder—Metformin—polycystic ovary syndrome	0.000317	0.0218	CcSEcCtD
Imipramine—HTR7—adrenal gland—polycystic ovary syndrome	0.000317	0.0087	CbGeAlD
Imipramine—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000316	0.0217	CcSEcCtD
Imipramine—CHRM3—female gonad—polycystic ovary syndrome	0.00031	0.00852	CbGeAlD
Imipramine—ADRA1A—adrenal gland—polycystic ovary syndrome	0.000306	0.00839	CbGeAlD
Imipramine—Malnutrition—Metformin—polycystic ovary syndrome	0.000306	0.021	CcSEcCtD
Imipramine—Dysgeusia—Metformin—polycystic ovary syndrome	0.000299	0.0205	CcSEcCtD
Imipramine—KCNH2—adrenal gland—polycystic ovary syndrome	0.000295	0.0081	CbGeAlD
Imipramine—HRH1—endometrium—polycystic ovary syndrome	0.000293	0.00803	CbGeAlD
Imipramine—CHRM3—endocrine gland—polycystic ovary syndrome	0.000289	0.00792	CbGeAlD
Imipramine—Vision blurred—Metformin—polycystic ovary syndrome	0.000288	0.0198	CcSEcCtD
Imipramine—HTR1A—endocrine gland—polycystic ovary syndrome	0.000288	0.00789	CbGeAlD
Imipramine—CYP2C19—vagina—polycystic ovary syndrome	0.000287	0.00787	CbGeAlD
Imipramine—Tremor—Metformin—polycystic ovary syndrome	0.000286	0.0197	CcSEcCtD
Imipramine—SLC6A2—endocrine gland—polycystic ovary syndrome	0.000285	0.00782	CbGeAlD
Imipramine—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000284	0.0195	CcSEcCtD
Imipramine—Malaise—Metformin—polycystic ovary syndrome	0.000276	0.0189	CcSEcCtD
Imipramine—KCNH2—female gonad—polycystic ovary syndrome	0.000275	0.00755	CbGeAlD
Imipramine—HTR7—endocrine gland—polycystic ovary syndrome	0.000275	0.00754	CbGeAlD
Imipramine—Syncope—Metformin—polycystic ovary syndrome	0.000274	0.0188	CcSEcCtD
Imipramine—KCNH2—vagina—polycystic ovary syndrome	0.000274	0.00751	CbGeAlD
Imipramine—Palpitations—Metformin—polycystic ovary syndrome	0.00027	0.0185	CcSEcCtD
Imipramine—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000269	0.0184	CcSEcCtD
Imipramine—CYP2C19—endocrine gland—polycystic ovary syndrome	0.000268	0.00736	CbGeAlD
Imipramine—ADRA1A—endocrine gland—polycystic ovary syndrome	0.000265	0.00727	CbGeAlD
Imipramine—Hypertension—Metformin—polycystic ovary syndrome	0.000264	0.0181	CcSEcCtD
Imipramine—HRH1—adipose tissue—polycystic ovary syndrome	0.000264	0.00724	CbGeAlD
Imipramine—DRD2—endocrine gland—polycystic ovary syndrome	0.00026	0.00713	CbGeAlD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000258	0.0177	CcSEcCtD
Imipramine—Discomfort—Metformin—polycystic ovary syndrome	0.000257	0.0176	CcSEcCtD
Imipramine—KCNH2—endocrine gland—polycystic ovary syndrome	0.000256	0.00703	CbGeAlD
Imipramine—Acepromazine—ADRA1B—polycystic ovary syndrome	0.000253	0.0558	CrCbGaD
Imipramine—Benazepril—MTHFR—polycystic ovary syndrome	0.000252	0.0556	CrCbGaD
Imipramine—Oedema—Metformin—polycystic ovary syndrome	0.000249	0.0171	CcSEcCtD
Imipramine—Infection—Metformin—polycystic ovary syndrome	0.000248	0.017	CcSEcCtD
Imipramine—Thioproperazine—ADRA1B—polycystic ovary syndrome	0.000247	0.0545	CrCbGaD
Imipramine—Shock—Metformin—polycystic ovary syndrome	0.000245	0.0168	CcSEcCtD
Imipramine—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000245	0.0168	CcSEcCtD
Imipramine—Epinastine—ADRA1A—polycystic ovary syndrome	0.000244	0.0539	CrCbGaD
Imipramine—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000244	0.0168	CcSEcCtD
Imipramine—CYP2B6—adrenal gland—polycystic ovary syndrome	0.000242	0.00665	CbGeAlD
Imipramine—Skin disorder—Metformin—polycystic ovary syndrome	0.000242	0.0166	CcSEcCtD
Imipramine—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000241	0.0166	CcSEcCtD
Imipramine—Anorexia—Metformin—polycystic ovary syndrome	0.000238	0.0163	CcSEcCtD
Imipramine—HRH1—adrenal gland—polycystic ovary syndrome	0.000237	0.00649	CbGeAlD
Imipramine—CYP2E1—adrenal gland—polycystic ovary syndrome	0.000227	0.00624	CbGeAlD
Imipramine—CYP2B6—vagina—polycystic ovary syndrome	0.000225	0.00616	CbGeAlD
Imipramine—Paraesthesia—Metformin—polycystic ovary syndrome	0.000224	0.0154	CcSEcCtD
Imipramine—Somnolence—Metformin—polycystic ovary syndrome	0.000222	0.0152	CcSEcCtD
Imipramine—HTR2A—pituitary gland—polycystic ovary syndrome	0.000221	0.00607	CbGeAlD
Imipramine—HRH1—female gonad—polycystic ovary syndrome	0.000221	0.00605	CbGeAlD
Imipramine—Nortriptyline—ADRA1D—polycystic ovary syndrome	0.00022	0.0486	CrCbGaD
Imipramine—Dyspepsia—Metformin—polycystic ovary syndrome	0.00022	0.0151	CcSEcCtD
Imipramine—HRH1—vagina—polycystic ovary syndrome	0.000219	0.00602	CbGeAlD
Imipramine—CYP1A2—endocrine gland—polycystic ovary syndrome	0.000219	0.00602	CbGeAlD
Imipramine—ABCB1—embryo—polycystic ovary syndrome	0.000219	0.00601	CbGeAlD
Imipramine—Decreased appetite—Metformin—polycystic ovary syndrome	0.000217	0.0149	CcSEcCtD
Imipramine—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000215	0.0148	CcSEcCtD
Imipramine—Fatigue—Metformin—polycystic ovary syndrome	0.000215	0.0148	CcSEcCtD
Imipramine—Constipation—Metformin—polycystic ovary syndrome	0.000213	0.0146	CcSEcCtD
Imipramine—CYP2B6—endocrine gland—polycystic ovary syndrome	0.00021	0.00577	CbGeAlD
Imipramine—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000206	0.0141	CcSEcCtD
Imipramine—Benazepril—ACE—polycystic ovary syndrome	0.000205	0.0453	CrCbGaD
Imipramine—HRH1—endocrine gland—polycystic ovary syndrome	0.000205	0.00563	CbGeAlD
Imipramine—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000204	0.014	CcSEcCtD
Imipramine—Methotrimeprazine—ADRA1D—polycystic ovary syndrome	0.000203	0.0447	CrCbGaD
Imipramine—Urticaria—Metformin—polycystic ovary syndrome	0.000198	0.0136	CcSEcCtD
Imipramine—HTR2A—adrenal gland—polycystic ovary syndrome	0.000198	0.00542	CbGeAlD
Imipramine—Doxepin—ADRA1D—polycystic ovary syndrome	0.000197	0.0436	CrCbGaD
Imipramine—CYP2E1—endocrine gland—polycystic ovary syndrome	0.000197	0.00541	CbGeAlD
Imipramine—Abdominal pain—Metformin—polycystic ovary syndrome	0.000197	0.0135	CcSEcCtD
Imipramine—Nortriptyline—ADRA1B—polycystic ovary syndrome	0.000188	0.0414	CrCbGaD
Imipramine—HTR2A—vagina—polycystic ovary syndrome	0.000183	0.00503	CbGeAlD
Imipramine—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000179	0.00492	CbGeAlD
Imipramine—Asthenia—Metformin—polycystic ovary syndrome	0.000179	0.0123	CcSEcCtD
Imipramine—Trimipramine—ADRA1B—polycystic ovary syndrome	0.000177	0.039	CrCbGaD
Imipramine—Pruritus—Metformin—polycystic ovary syndrome	0.000176	0.0121	CcSEcCtD
Imipramine—Promazine—ADRA1D—polycystic ovary syndrome	0.000175	0.0387	CrCbGaD
Imipramine—Methotrimeprazine—ADRA1B—polycystic ovary syndrome	0.000173	0.0381	CrCbGaD
Imipramine—HTR2A—endocrine gland—polycystic ovary syndrome	0.000171	0.0047	CbGeAlD
Imipramine—Diarrhoea—Metformin—polycystic ovary syndrome	0.000171	0.0117	CcSEcCtD
Imipramine—Acepromazine—ADRA1A—polycystic ovary syndrome	0.00017	0.0376	CrCbGaD
Imipramine—Doxepin—ADRA1B—polycystic ovary syndrome	0.000168	0.0372	CrCbGaD
Imipramine—CYP2D6—female gonad—polycystic ovary syndrome	0.000168	0.00461	CbGeAlD
Imipramine—Thioproperazine—ADRA1A—polycystic ovary syndrome	0.000166	0.0367	CrCbGaD
Imipramine—Dizziness—Metformin—polycystic ovary syndrome	0.000165	0.0113	CcSEcCtD
Imipramine—ABCB1—endometrium—polycystic ovary syndrome	0.00016	0.0044	CbGeAlD
Imipramine—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000159	0.00435	CbGeAlD
Imipramine—Vomiting—Metformin—polycystic ovary syndrome	0.000159	0.0109	CcSEcCtD
Imipramine—Rash—Metformin—polycystic ovary syndrome	0.000157	0.0108	CcSEcCtD
Imipramine—Dermatitis—Metformin—polycystic ovary syndrome	0.000157	0.0108	CcSEcCtD
Imipramine—Headache—Metformin—polycystic ovary syndrome	0.000156	0.0107	CcSEcCtD
Imipramine—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000156	0.00428	CbGeAlD
Imipramine—Amitriptyline—ADRA1D—polycystic ovary syndrome	0.000153	0.0337	CrCbGaD
Imipramine—Promazine—ADRA1B—polycystic ovary syndrome	0.00015	0.033	CrCbGaD
Imipramine—Nausea—Metformin—polycystic ovary syndrome	0.000148	0.0102	CcSEcCtD
Imipramine—ABCB1—uterus—polycystic ovary syndrome	0.000148	0.00405	CbGeAlD
Imipramine—ABCB1—pituitary gland—polycystic ovary syndrome	0.000145	0.00398	CbGeAlD
Imipramine—ABCB1—adipose tissue—polycystic ovary syndrome	0.000144	0.00396	CbGeAlD
Imipramine—Chlorpromazine—ADRA1B—polycystic ovary syndrome	0.000132	0.0291	CrCbGaD
Imipramine—Amitriptyline—ADRA1B—polycystic ovary syndrome	0.00013	0.0288	CrCbGaD
Imipramine—ABCB1—adrenal gland—polycystic ovary syndrome	0.000129	0.00355	CbGeAlD
Imipramine—Nortriptyline—ADRA1A—polycystic ovary syndrome	0.000126	0.0279	CrCbGaD
Imipramine—ABCB1—female gonad—polycystic ovary syndrome	0.000121	0.00331	CbGeAlD
Imipramine—ABCB1—vagina—polycystic ovary syndrome	0.00012	0.00329	CbGeAlD
Imipramine—Trimipramine—ADRA1A—polycystic ovary syndrome	0.000119	0.0263	CrCbGaD
Imipramine—Methotrimeprazine—ADRA1A—polycystic ovary syndrome	0.000116	0.0257	CrCbGaD
Imipramine—Promethazine—ADRA1A—polycystic ovary syndrome	0.000115	0.0253	CrCbGaD
Imipramine—Doxepin—ADRA1A—polycystic ovary syndrome	0.000113	0.025	CrCbGaD
Imipramine—ABCB1—endocrine gland—polycystic ovary syndrome	0.000112	0.00308	CbGeAlD
Imipramine—Promazine—ADRA1A—polycystic ovary syndrome	0.000101	0.0222	CrCbGaD
Imipramine—Chlorpromazine—ADRA1A—polycystic ovary syndrome	8.87e-05	0.0196	CrCbGaD
Imipramine—Amitriptyline—ADRA1A—polycystic ovary syndrome	8.77e-05	0.0194	CrCbGaD
Imipramine—Desipramine—ADRB2—polycystic ovary syndrome	6.19e-05	0.0137	CrCbGaD
Imipramine—CHRM5—Signaling Pathways—IRS1—polycystic ovary syndrome	3.29e-06	2.75e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—INS—polycystic ovary syndrome	3.29e-06	2.75e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—GNAS—polycystic ovary syndrome	3.27e-06	2.73e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—GNAS—polycystic ovary syndrome	3.27e-06	2.72e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—NCOR1—polycystic ovary syndrome	3.24e-06	2.7e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.23e-06	2.69e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	3.21e-06	2.68e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.21e-06	2.68e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.2e-06	2.67e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—IGF1—polycystic ovary syndrome	3.19e-06	2.66e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—AKT2—polycystic ovary syndrome	3.18e-06	2.66e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.18e-06	2.65e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—NCOR1—polycystic ovary syndrome	3.17e-06	2.65e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—POMC—polycystic ovary syndrome	3.17e-06	2.65e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.17e-06	2.65e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—NRG1—polycystic ovary syndrome	3.17e-06	2.64e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.16e-06	2.64e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—INS—polycystic ovary syndrome	3.15e-06	2.63e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.15e-06	2.63e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—TH—polycystic ovary syndrome	3.15e-06	2.63e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—PPARG—polycystic ovary syndrome	3.14e-06	2.62e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—PPARG—polycystic ovary syndrome	3.14e-06	2.62e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.12e-06	2.6e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—NRG1—polycystic ovary syndrome	3.12e-06	2.6e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—NRG1—polycystic ovary syndrome	3.11e-06	2.6e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.11e-06	2.6e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—NRG1—polycystic ovary syndrome	3.1e-06	2.59e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—POMC—polycystic ovary syndrome	3.1e-06	2.58e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—IRS1—polycystic ovary syndrome	3.1e-06	2.58e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—POMC—polycystic ovary syndrome	3.09e-06	2.58e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IRS2—polycystic ovary syndrome	3.09e-06	2.58e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—NRG1—polycystic ovary syndrome	3.09e-06	2.58e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	3.09e-06	2.58e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—INS—polycystic ovary syndrome	3.08e-06	2.57e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IRS2—polycystic ovary syndrome	3.08e-06	2.57e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—INS—polycystic ovary syndrome	3.08e-06	2.57e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—TH—polycystic ovary syndrome	3.07e-06	2.56e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—CYP1A1—polycystic ovary syndrome	3.07e-06	2.56e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	3.07e-06	2.56e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	3.06e-06	2.56e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—NRG1—polycystic ovary syndrome	3.06e-06	2.55e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—NRG1—polycystic ovary syndrome	3.05e-06	2.55e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—IGF1—polycystic ovary syndrome	3.05e-06	2.55e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	3.05e-06	2.55e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	3.05e-06	2.55e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—AKT2—polycystic ovary syndrome	3.05e-06	2.54e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	3.03e-06	2.53e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—LEP—polycystic ovary syndrome	3.03e-06	2.52e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.03e-06	2.52e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—LEP—polycystic ovary syndrome	3.01e-06	2.51e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—CYP1A1—polycystic ovary syndrome	3.01e-06	2.51e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	2.99e-06	2.49e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—POMC—polycystic ovary syndrome	2.98e-06	2.49e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	2.98e-06	2.49e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—INS—polycystic ovary syndrome	2.97e-06	2.47e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IRS2—polycystic ovary syndrome	2.94e-06	2.46e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PPARG—polycystic ovary syndrome	2.92e-06	2.44e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.9e-06	2.42e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—TH—polycystic ovary syndrome	2.9e-06	2.42e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	2.89e-06	2.41e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—POMC—polycystic ovary syndrome	2.88e-06	2.41e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—LEP—polycystic ovary syndrome	2.88e-06	2.4e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	2.88e-06	2.4e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	2.88e-06	2.4e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—IGF1—polycystic ovary syndrome	2.87e-06	2.39e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—AKT2—polycystic ovary syndrome	2.87e-06	2.39e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—INS—polycystic ovary syndrome	2.87e-06	2.39e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—MTHFR—polycystic ovary syndrome	2.86e-06	2.39e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	2.84e-06	2.37e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	2.82e-06	2.35e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	2.81e-06	2.35e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—MTHFR—polycystic ovary syndrome	2.81e-06	2.34e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.72e-06	2.27e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	2.71e-06	2.27e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PPARG—polycystic ovary syndrome	2.7e-06	2.25e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.7e-06	2.25e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IRS1—polycystic ovary syndrome	2.69e-06	2.24e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	2.67e-06	2.23e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IRS2—polycystic ovary syndrome	2.67e-06	2.22e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—POMC—polycystic ovary syndrome	2.66e-06	2.22e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	2.66e-06	2.22e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IRS2—polycystic ovary syndrome	2.66e-06	2.22e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	2.66e-06	2.22e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	2.65e-06	2.21e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IRS2—polycystic ovary syndrome	2.65e-06	2.21e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—INS—polycystic ovary syndrome	2.65e-06	2.21e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IRS2—polycystic ovary syndrome	2.62e-06	2.19e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IRS2—polycystic ovary syndrome	2.62e-06	2.18e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	2.61e-06	2.18e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—LEP—polycystic ovary syndrome	2.61e-06	2.18e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—LEP—polycystic ovary syndrome	2.6e-06	2.17e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—POMC—polycystic ovary syndrome	2.6e-06	2.17e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—LEP—polycystic ovary syndrome	2.59e-06	2.16e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—POMC—polycystic ovary syndrome	2.59e-06	2.16e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—INS—polycystic ovary syndrome	2.58e-06	2.16e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling by GPCR—IL6—polycystic ovary syndrome	2.58e-06	2.16e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling by GPCR—IL6—polycystic ovary syndrome	2.58e-06	2.15e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	2.57e-06	2.15e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—INS—polycystic ovary syndrome	2.57e-06	2.15e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	2.57e-06	2.14e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IRS1—polycystic ovary syndrome	2.57e-06	2.14e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—LEP—polycystic ovary syndrome	2.57e-06	2.14e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—LEP—polycystic ovary syndrome	2.56e-06	2.14e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	2.51e-06	2.09e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.5e-06	2.09e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.5e-06	2.08e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IGF1—polycystic ovary syndrome	2.49e-06	2.08e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—AKT2—polycystic ovary syndrome	2.49e-06	2.07e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	2.48e-06	2.07e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—POMC—polycystic ovary syndrome	2.48e-06	2.07e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—INS—polycystic ovary syndrome	2.46e-06	2.05e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—TH—polycystic ovary syndrome	2.45e-06	2.05e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	2.45e-06	2.04e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling by GPCR—IL6—polycystic ovary syndrome	2.44e-06	2.03e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	2.39e-06	1.99e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	2.39e-06	1.99e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	2.38e-06	1.99e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IGF1—polycystic ovary syndrome	2.38e-06	1.99e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—AKT2—polycystic ovary syndrome	2.38e-06	1.99e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.37e-06	1.98e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.37e-06	1.98e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	2.36e-06	1.97e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.36e-06	1.97e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	2.35e-06	1.96e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling by GPCR—IL6—polycystic ovary syndrome	2.33e-06	1.95e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.33e-06	1.95e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.33e-06	1.94e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PPARG—polycystic ovary syndrome	2.32e-06	1.94e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	2.32e-06	1.94e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.32e-06	1.94e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IRS1—polycystic ovary syndrome	2.31e-06	1.93e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—POMC—polycystic ovary syndrome	2.29e-06	1.91e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.29e-06	1.91e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.28e-06	1.91e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	2.28e-06	1.9e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—INS—polycystic ovary syndrome	2.28e-06	1.9e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PPARG—polycystic ovary syndrome	2.27e-06	1.9e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	2.27e-06	1.89e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	2.27e-06	1.89e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.26e-06	1.89e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	2.25e-06	1.88e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	2.25e-06	1.87e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	2.24e-06	1.87e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—POMC—polycystic ovary syndrome	2.24e-06	1.87e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—POMC—polycystic ovary syndrome	2.24e-06	1.87e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—POMC—polycystic ovary syndrome	2.23e-06	1.86e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	2.23e-06	1.86e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—INS—polycystic ovary syndrome	2.23e-06	1.86e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—INS—polycystic ovary syndrome	2.23e-06	1.86e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—POMC—polycystic ovary syndrome	2.23e-06	1.86e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	2.22e-06	1.85e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—INS—polycystic ovary syndrome	2.22e-06	1.85e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—INS—polycystic ovary syndrome	2.21e-06	1.85e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.21e-06	1.84e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—POMC—polycystic ovary syndrome	2.2e-06	1.84e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.2e-06	1.84e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—POMC—polycystic ovary syndrome	2.2e-06	1.83e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.2e-06	1.83e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—IL6—polycystic ovary syndrome	2.19e-06	1.83e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.19e-06	1.83e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—INS—polycystic ovary syndrome	2.19e-06	1.83e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	2.19e-06	1.83e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—INS—polycystic ovary syndrome	2.19e-06	1.82e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	2.16e-06	1.81e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.16e-06	1.8e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.16e-06	1.8e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.16e-06	1.8e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.15e-06	1.8e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.15e-06	1.79e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.15e-06	1.79e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IGF1—polycystic ovary syndrome	2.14e-06	1.79e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—AKT2—polycystic ovary syndrome	2.14e-06	1.79e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	2.14e-06	1.78e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.12e-06	1.77e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.12e-06	1.77e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.11e-06	1.76e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.11e-06	1.76e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	2.11e-06	1.76e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.08e-06	1.74e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.08e-06	1.74e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.05e-06	1.71e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.05e-06	1.71e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.04e-06	1.7e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.03e-06	1.7e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.01e-06	1.68e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.01e-06	1.68e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	2e-06	1.67e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.99e-06	1.66e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	1.99e-06	1.66e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.91e-06	1.6e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	1.91e-06	1.59e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—IL6—polycystic ovary syndrome	1.9e-06	1.59e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—TH—polycystic ovary syndrome	1.89e-06	1.58e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.87e-06	1.56e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	1.84e-06	1.54e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—IL6—polycystic ovary syndrome	1.82e-06	1.52e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	1.81e-06	1.51e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	1.76e-06	1.46e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	1.73e-06	1.45e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	1.73e-06	1.44e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—INS—polycystic ovary syndrome	1.72e-06	1.44e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	1.71e-06	1.43e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—POMC—polycystic ovary syndrome	1.69e-06	1.41e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	1.69e-06	1.41e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—INS—polycystic ovary syndrome	1.68e-06	1.4e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.68e-06	1.4e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.65e-06	1.38e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.65e-06	1.38e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.64e-06	1.37e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—IL6—polycystic ovary syndrome	1.64e-06	1.37e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.63e-06	1.36e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.62e-06	1.36e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.62e-06	1.35e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.62e-06	1.35e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	1.61e-06	1.35e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	1.59e-06	1.33e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—INS—polycystic ovary syndrome	1.58e-06	1.32e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.56e-06	1.3e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	1.55e-06	1.29e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—IL6—polycystic ovary syndrome	1.53e-06	1.27e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—IL6—polycystic ovary syndrome	1.52e-06	1.27e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	1.47e-06	1.23e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—IL6—polycystic ovary syndrome	1.44e-06	1.2e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.43e-06	1.2e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.41e-06	1.18e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.41e-06	1.17e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.4e-06	1.17e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.4e-06	1.17e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	1.4e-06	1.16e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.39e-06	1.16e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.38e-06	1.15e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—IL6—polycystic ovary syndrome	1.38e-06	1.15e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	1.37e-06	1.14e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	1.35e-06	1.13e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—INS—polycystic ovary syndrome	1.34e-06	1.12e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	1.3e-06	1.09e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—IL6—polycystic ovary syndrome	1.3e-06	1.08e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IL6—polycystic ovary syndrome	1.13e-06	9.42e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.12e-06	9.38e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IL6—polycystic ovary syndrome	1.08e-06	8.97e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.06e-06	8.81e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.04e-06	8.68e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.04e-06	8.64e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	9.92e-07	8.27e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	9.76e-07	8.14e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IL6—polycystic ovary syndrome	9.74e-07	8.12e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IL6—polycystic ovary syndrome	9.71e-07	8.1e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IL6—polycystic ovary syndrome	9.67e-07	8.07e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IL6—polycystic ovary syndrome	9.58e-07	7.99e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IL6—polycystic ovary syndrome	9.55e-07	7.97e-06	CbGpPWpGaD
